Soybean meal is a bi-product following oil extraction from soybean seeds. It is rich in protein, which usually makes up around 40% of the nutritional components of the seeds and dependent on the line, and can also contain high oleic acid (a monounsaturated omega-9 fatty acid).
The study looked at the role soybeans could have in the prevention of cancer. Using a variety of soybean lines which were high in oleic acid and protein, the researchers looked to monitor bioactivity between the peptides derived from the meals of soybean and various types of human cancer cells.
The study showed that peptides derived from soybean meal significantly inhibited cell growth by 73% for colon cancer, 70% for liver cancer and 68% for lung cancer cells using human cell lines. This shows that the selected high oleic acid soybean lines could have a potential nutraceutical affect in helping to reduce the growth of several types of cancer cells.
Notes for editors
This article is "Peptides derived from high oleic acid soybean meals inhibit colon, liver and lung cancer cell growth" by Srinivas J. Rayaprolu, Navam S. Hettiarachchy, Pengyin Chen, Arvind Kannan and Andronikos Mauromostakos
(DOI: 10.1016/j.foodres.2012.10.021) and appears in Food Research International published by Elsevier.
The article is available to credentialed journalists at no charge through free access to ScienceDirect, the world's largest repository of scientific information. Please use your ScienceDirect media login and password to access the full text research paper. For a new media login, forgotten password or if you have any specific questions, please contact email@example.com
If you are a credentialed journalist and are interested in receiving other research alerts from Elsevier, please sign up for Elsevier's Monthly Research Selection (EMRS) - a monthly email developed by the Elsevier Newsroom which highlights new, interesting or otherwise intriguing research articles for health and science media. The full text research articles included are peer reviewed and have been publicly available for no more than 4-6 weeks (they are usually articles-in-press). They have not been press-released nor covered in the media (that we are aware of) and they are not embargoed.
If you would like to sign up for the EMRS please send an email to firstname.lastname@example.org